FDA Taking Closer Look at Manufacturers’ Visual Testing Programs While USP Would Set New Limits for Particles
This article was originally published in The Gold Sheet
Executive Summary
FDA investigators are taking a closer look at parenteral manufacturers’ inspections for visible particles while a proposed USP standard would give more guidance – and much needed clarity – on establishing acceptable quality limits for particles and setting up visual inspection programs.
You may also be interested in...
FDA Investigators Finding Fewer Deficiencies For Visual Inspection Programs
Experts on visual inspection and patient risk attribute a downward trend in inadequate visual inspection plans for particles to a new USP chapter that offers greater clarity on testing conditions. While there is negligible safety risk posed by visible particles, manufacturers should still conduct particle characterization studies. And no, glass particles are not risker than metal or wood particles.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.